Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 15/20 | 1.00 |
| ▸ | NR1H3 | Q13133 | 15/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | POLA1 | P09884 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6312606 | 0.91 | NR1H2 (1.00) | NR1H2NR1H3 | |
| SCHEMBL6318131 | 0.89 | NR1H2 (0.96) | NR1H2NR1H3 | |
| SCHEMBL6309953 | 0.86 | NR1H2 (0.76) | NR1H2NR1H3POLA1 | |
| SCHEMBL6309960 | 0.85 | NR1H2 (0.75) | NR1H2NR1H3POLA1 | |
| SCHEMBL6311870 | 0.83 | NR1H2 (0.74) | NR1H2NR1H3POLA1 | |
| SCHEMBL6310992 | 0.80 | NR1H2 (0.81) | NR1H2NR1H3POLA1 | |
| SCHEMBL6318781 | 0.80 | NR1H2 (0.80) | NR1H2NR1H3POLA1 | |
| SCHEMBL6311679 | 0.79 | NR1H2 (0.68) | NR1H2NR1H3POLA1 | |
| SCHEMBL31181392 | 0.78 | POLA1 (0.68) | NR1H2NR1H3POLA1 | |
| SCHEMBL20359348 | 0.78 | POLA1 (0.68) | NR1H2NR1H3POLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6908934-B2 | Therapeutic compounds for treating dyslipidemic conditions | MERCK & CO., INC. (US) | 2005-06-21 | — | — | US | disclosed |
| US-20030125357-A1 | Therapeutic compounds for treating dyslipidemic conditions | MERCK & CO., INC. | 2003-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125357-A1 | Therapeutic compounds for treating dyslipidemic conditions | NR1H2, NR1H3, APOB | NR1H2 1/4885NR1H3 2/4885LMNA 840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.